Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient'survival and quality of life. In 2000, professor Chunxiao Liu invented "detaenial sigmoid neobladder", this surgical method overset the traditional intestinal detubularization approach, which detached the serosal layer with smooth muscle from the bowel without split it. This kind of neobladder is easier to construct and have less impact on intestinal function. So far, it has been implemented for more than 700 cases in Zhujiang hospital, the age of patients range from 9 months (bladder rhabdomyosarcoma) to 88 years old. The filed of standard radical bladder cancer resection includes the structure of the prostate and seminal vesicles. More and more studies and long-term clinical experience in our hospital have confirmed that capsule sparing cystectomy can achieve good tumor control and excellent functional recovery. Our project is going to perform a randomized controlled trial for capsule sparing cystectomy and conventional radical cystoprostatectomy and look forward to assess the oncology outcome and functional recovery of these two procedures which provide an objective basis for the patients undergoing orthotopic urinary diversion in the future.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni powyżej 20 lat
- •Rak pęcherza moczowego w stadium T1-T3, bez przerzutów do węzłów chłonnych i narządów odległych
- •Nawracający rak pęcherza po wcześniejszym leczeniu
- •Ogólny stan zdrowia pacjenta pozwalający na operację (skala ECOG 0-1)
- •Dobrowolnie podpisana zgoda na udział w badaniu
✗ Disqualifies
- •Zaburzona funkcja nerek (kreatynina powyżej normy)
- •Rak rozszerzył się na prostatę lub moczowód (potwierdzone badaniem)
- •Przerzuty raka do odległych organów
- •Podejrzenie niediagnozowanego raka prostaty
- •Inne nowotwory w ostatnich 3 latach
- •Przewlekłe zapalenie jelita grubego lub gruźlica jelit
- •Poważne problemy z sercem, płucami lub wątrobą
- •Inne schorzenia uznane przez urologa za przeciwwskazania do operacji
Simplified criteria — AI translation
Trial details
- Minimum age
- 20 Years
- Last updated (source)
- October 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Chunxiao Liu
Guangzhou, China
Trial contact
Chunxiao Liu, doctor
Peng Xu, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.